A team of Sidley lawyers represented Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, in an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases.
“This novel approach is part of Vera’s broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we treat patients suffering from a variety of B cell mediated diseases. We plan to leverage our research, translational medicine, clinical development and commercial expertise to define and advance the potential of this molecule,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “This transaction furthers our commitment to transforming outcomes for patients with grievous autoimmune diseases.”
This agreement will enable Vera to develop and market VT-109 in return for undisclosed upfront and milestone payments. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients.
The Sidley team was led by Sidley partner Stephen Abreu and included Collin J Marshall and Sophia Iams (Technology and Life Sciences Transactions); Carlton Fleming (Emerging Companies and Venture Capital); and Scott T. Nonaka (Global Arbitration, Trade and Advocacy).
For additional details, please refer to the press release.
